Replies to post #334072 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine works way beyond sigma-1.

You might want to add that 2-73 is a muscaric receptor agonist in addition to being a Sigma-1 agonist.

Steady_T, you are right. To keep complicated (some would say, “tricky”) things simple, I stay focused on blarcamesine’s activation of the sigma-1 receptor protein. That, alone, makes both blarcamesine and Anavex Life Sciences Corp winners.

But you are correct. The story is much larger than just the sigma-1 receptor. There are “muscarinic” receptors, very different (in function) from the sigma-1 receptor. Propitious activation of muscarinic receptors by blarcamesine produces a diversity of favorable processes and outcomes; for which many remain to be discovered or utilized.

Blarcamesine. Bigger and better than anything on any pharmacy shelf, working so favorably in a diversity of ways, against a wide diversity of diseases and conditions. Until demonstrated in proper human clinical trials, a story (or molecule) too good to be true.

Check back on this in late 2022. Trial results will be definitive.

Then, on out, blarcamesine and Anavex 3-71 will be eagerly tested for a broad range of human (and animal) health problems. 2022 will close with only the first chapter in the Anavex story. Many after that; including muscarinic receptor applications.